What is TechsoMed?
TechsoMed is a privately held medical imaging software company focused on revolutionizing diagnostic capabilities. Its flagship BioTrace platform utilizes advanced AI and standard commercial ultrasound imaging to enable physicians to detect and visualize tissue viability. This innovative technology finds application in critical clinical areas such as oncology for tumor ablation, cardiology for heart arrhythmia monitoring, and pain management through radiofrequency neurotomy, offering real-time image analysis across multiple specialties.
How much funding has TechsoMed raised?
TechsoMed has raised a total of $9.6M across 2 funding rounds:
Other Financing Round
$2.6M
Series B
$7M
Other Financing Round (2019): $2.6M with participation from Axil Capital, Screen Holdings, JJDC, NextLeap Ventures, and AMIT-Technion
Series B (2021): $7M led by JJDC, JLABS companies, Radianx Capital, NextLeap Ventures, Cobro Ventures, Magna Capital Partners, Yonjin Venture, and Axil Capital
Key Investors in TechsoMed
JJDC
JJDC, part of Johnson & Johnson Innovation, is a venture capital arm focused on investing in early-stage healthcare companies. Their investment in TechsoMed suggests a strategic interest in novel medical technologies that can enhance diagnostic and therapeutic capabilities.
Magna Capital Partners
Magna Capital Partners is an investment firm that emphasizes collaborative and forward-looking partnerships, aiming to create value within businesses. Their participation indicates a belief in TechsoMed's long-term potential and strategic market positioning.
JJDC
JJDC, associated with Johnson & Johnson, has a history of supporting innovative healthcare ventures. Their continued investment in TechsoMed highlights their confidence in the company's technology and its potential to impact patient care.
What's next for TechsoMed?
With the recent major strategic investment, TechsoMed is poised for accelerated growth and market penetration. The company's focus on AI-driven medical imaging solutions addresses a critical need for enhanced diagnostic precision in complex procedures. This backing will likely fuel further research and development, expand clinical validation, and support the commercialization of the BioTrace platform, positioning TechsoMed as a key player in the evolving landscape of medical technology.
See full TechsoMed company page
